Skip to main content

OrbiMed Advisors LLC's Form 4/A amendment

Amended

Passage BIO, Inc. (PASG) · filed May 5, 2022

Accession no.
0000947871-22-000507
Filed
May 5, 2022, 5:11 PM ET
Trade date
Jan 20, 2022
Filing delay
105 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Jan 24, 2022

This filing lists 1 non-derivative transaction. Open-market purchases total $254.0K. It was filed 105 days after the trade.

This amendment replaces 0000947871-22-000090 (filed Jan 24, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 000105595110% Owner
OrbiMed Capital GP VII LLCCIK 000176064810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 20, 2022Common StockPPurchaseAcquired+50,800$5.00F1,F2+$254,0006,316,423Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On January 24, 2022, the Reporting Person filed a Form 4 which inadvertently reported the incorrect number and purchase price of shares of the Issuer's common stock ("Shares") purchased by the reporting person on January 20, 2022. This amendment provides the correct number and purchase price of the Shares purchased and correctly reflects the number of Shares owned by the Reporting Person following such purchase.

Referenced by the price of 1 transaction in Table I.

F2

These Shares were purchased in a block order at a price of $5.00.

Referenced by the price of 1 transaction in Table I.

F3

The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F4

Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Read the full filing on SEC EDGAR (opens in a new tab)